BPC-157: Complete Research Guide for 2026

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein found in gastric juice. The parent protein, described in literature as a "stomach peptide," was identified by Croatian researcher Dieter Sikiric and colleagues at the University of Zagreb in the 1990s, who isolated and characterized the biologically active fragment now known as BPC-157.

The compound is designated as a research peptide and does not hold approved drug status in the United States, European Union, or any other major regulatory jurisdiction as of early 2026. All human use has occurred either outside formal regulatory frameworks or within informal clinical settings. There are no completed Phase II or Phase III human clinical trials published in peer-reviewed literature.

The amino acid sequence of BPC-157 is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

Proposed Mechanisms of Action

BPC-157's observed effects in animal models are diverse and span multiple biological systems. Researchers have proposed several mechanisms, though none have been definitively characterized in human tissue:

Nitric Oxide (NO) System Modulation

A substantial body of preclinical literature implicates the nitric oxide pathway as central to BPC-157's activity. Studies suggest that BPC-157 can upregulate endothelial nitric oxide synthase (eNOS) expression and modulate NO production in a context-dependent manner — increasing it in conditions of deficiency and stabilizing it in conditions of excess. This may underlie some of the observed vascular and tissue-healing effects.

Growth Factor Upregulation

BPC-157 has been shown in rodent models to increase the expression of growth factors including VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor). These effects are thought to contribute to accelerated wound healing, angiogenesis, and tissue regeneration observed in studies.

Interaction with the Dopaminergic and Serotonergic Systems

Several published studies from the Zagreb group and independent researchers have examined BPC-157's effects on monoamine neurotransmission. The compound appears to modulate dopamine and serotonin receptor sensitivity, which has been proposed as a mechanism for its observed effects in models of depression, stress, and neurological injury.

Tendon and Ligament Fibroblast Stimulation

In cell culture and in vivo tendon injury models, BPC-157 has demonstrated the ability to increase the outgrowth and proliferation of tendon fibroblasts and to accelerate the maturation of collagen in healing tendon tissue. This has made musculoskeletal applications one of the most extensively studied areas.

Gut-Brain Axis Effects

Given its origin as a gastric protein fragment, BPC-157's effects on the gastrointestinal tract are among the most reproduced findings in the literature. Animal studies have demonstrated efficacy in models of inflammatory bowel disease, gastric ulcers, intestinal fistula, and surgical anastomosis healing.

Evidence Overview

Preclinical Evidence

The preclinical evidence base for BPC-157 is substantial by peptide research standards. Over 200 peer-reviewed papers have been published, the majority from Sikiric's group, examining effects in rat and mouse models across the following domains:

• Wound healing and tissue repair: Multiple studies report accelerated healing of skin wounds, muscle tears, and bone fractures in rodent models.
• Gastrointestinal protection: Consistent findings in models of NSAID-induced gut injury, inflammatory bowel disease, and esophageal lesions.
• Tendon and ligament repair: Perhaps the strongest and most independently replicated area; effects on Achilles tendon, patellar tendon, and rotator cuff models have been studied.
• Neurological models: Effects in models of traumatic brain injury, spinal cord damage, and dopaminergic neurotoxicity have been reported, though replication by independent groups is more limited.
• Cardiovascular protection: Studies in cardiac ischemia-reperfusion models have shown protective effects attributed to NO pathway modulation.

The Independent Replication Problem

A limitation that any serious review of BPC-157 must acknowledge: a disproportionate share of the published literature originates from a single research group. Independent replication — particularly in non-rodent models and by investigators without financial or institutional relationships to the original team — is limited. This is a meaningful constraint on the strength of inference that can be drawn from the existing data.

Several independent groups have published confirming results in wound healing and tendon repair, which increases confidence in those specific applications. The neurological and systemic findings require substantially more independent validation.

Human Evidence

There are no published Phase II or Phase III randomized controlled trials of BPC-157 in human subjects. A small number of anecdotal clinical case series exist, primarily from practitioners outside mainstream academic medicine. These do not constitute clinical evidence by any accepted evidentiary standard.

Common Research Applications and Dosing in Studies

The following reflects dosing approaches documented in preclinical studies and should be understood strictly in that context.

Animal Study Dosing Patterns

In the majority of rodent studies, BPC-157 is administered at doses ranging from 1–10 mcg/kg intraperitoneally or subcutaneously. Some studies have used oral gavage at substantially higher doses (1–100 mg/kg) given the compound's apparent resistance to gastric degradation. The route of administration in published studies varies widely based on the outcome being studied.

Studies focusing on systemic effects (gut healing, wound repair, neurological endpoints) have most commonly used IP injection at 10 mcg/kg once daily. Tendon and musculoskeletal studies have used both systemic and local (peritendinous) injection with comparable results reported.

Half-Life and Stability

BPC-157 has a short plasma half-life, estimated at under 4 hours based on pharmacokinetic data in rodents. The peptide demonstrates unusual stability in gastric acid, which has been cited as the basis for its oral activity in GI models — a property not commonly seen with other peptides of similar structure.

Side Effect Profile

Based on the available preclinical data, BPC-157 has demonstrated a favorable safety profile across a wide range of doses in animal studies. No LD50 has been established in rodent toxicology studies — doses far exceeding those used in efficacy studies have not produced observable toxicity. No significant adverse effects on organ function, hematological parameters, or histopathological markers were observed in published rodent studies.

The absence of identified toxicity in preclinical models should not be extrapolated to safety in humans. Standard principles of translational pharmacology apply: rodent safety data does not confirm human safety, and the absence of evidence of harm in animal studies is not evidence of absence of harm in humans.

No long-term carcinogenicity, genotoxicity, or reproductive toxicology studies have been published in peer-reviewed literature.

Current Regulatory Status (2026)

BPC-157 was placed on the FDA's Category 2 bulk drug substances list in late 2024, meaning that 503A compounding pharmacies and 503B outsourcing facilities in the United States may no longer compound it for human therapeutic use. This decision reflects the FDA's determination that available evidence is insufficient to support compounding under current standards — not a finding of specific known toxicity.

Outside the United States, BPC-157 occupies a regulatory grey area in most jurisdictions. It is not approved as a drug product anywhere, but its legal status as a research compound varies by country.

For preclinical research purposes, BPC-157 can be obtained from qualified research chemical suppliers. Researchers planning human studies would be required to submit an Investigational New Drug (IND) application to the FDA and obtain IRB approval before administering the compound to human subjects.

Where the Research Is Heading

Despite the regulatory headwinds, scientific interest in BPC-157 has not diminished. Several groups are pursuing IND-enabling studies with the goal of initiating Phase I safety trials. The compound's multi-system activity and apparent safety profile in animals make it an attractive candidate for indications where approved therapies are limited — particularly in gastrointestinal conditions and connective tissue repair.

Whether BPC-157 will ultimately demonstrate clinical efficacy and safety in well-designed human trials remains an open question. The preclinical data is intriguing, but the path from intriguing animal data to an approved therapeutic has historically been long, expensive, and often disappointing. The peptide research community is watching this development closely.